• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Canada·Healthcare·BHC
Held by 3 Gurus
Share

Bausch Health Companies Inc. Stocks

$ 6.16Last Updated 09.09.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

$ 2.41B

$ 6.16
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

Bridgewater Associates

Steven Cohen

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

Point72 Asset Management, L.P.

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.00%
Steven CohenPoint72 Asset Management, L.P.0.0%+0.00%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of BHC is 7.90 and suggests 28.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.09.2026 20:22

Europe's largest airline has warned of the risk of a "significant increase" in prices due to oil prices

10.09.2026 19:47

A Historic Shift: BlackRock Proposes an Alternative to the 60/40 Portfolio

10.09.2026 19:09

"A Bit of Chaos": How Sergey Brin Is Building Gemini in Startup Style in a Kitchen at Google

10.09.2026 18:40

The Nasdaq fell 1% at the start of trading in the U.S. due to a sharp rise in oil prices

10.09.2026 18:17

Pet supplies retailer Chewy has worst day in a year amid 'unremarkable' results

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026